PF-Atlas › Clinical Trials › NCT07450547
Phase 2 Study to Assess the Safety and Efficacy of ANG003
ANG003 Dose A · Phase 2
Registry ID
NCT07450547
Phase
Phase 2
Status
Recruiting
Drug / intervention
ANG003 Dose A
Sponsor
Anagram Therapeutics, Inc.
Start
2026-04-24
Enrollment
113
Locations
26
About this trial
In this study, ANG003, a pancreatic enzyme replacement therapy (PERT; commonly called "enzymes"), is being investigated as a potential treatment for exocrine pancreatic insufficiency (EPI). People with EPI due to Cystic Fibrosis (CF) may be eligible to participate in this study. The primary objective of this study is to evaluate the safety of ANG003 and see if it works as well compared to Creon, an approved PERT.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT07450547 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.